ADARx Pharmaceuticals (NASDAQ:ADRX) Director Erez Chimovits Purchases 61,516 Shares of Company Stock

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Erez Chimovits bought 61,516 shares of ADARx Pharmaceuticals stock in a transaction on Monday, September 28th. The stock was purchased at an average price of $17.00 per share, with a total value of $1,045,772.00. Following the completion of the acquisition, the director directly owned 9,292,025 shares of the company’s stock, valued at $157,964,425. This represents a 0.67% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

ADARx Pharmaceuticals Stock Performance

Shares of NASDAQ:ADRX traded down $0.70 during trading on Wednesday, reaching $19.94. The stock had a trading volume of 788,778 shares, compared to its average volume of 1,097,539. ADARx Pharmaceuticals, Inc. has a one year low of $18.50 and a one year high of $23.21.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.